The report, obtained by Becker’s Hospital Review, identifies 10 healthcare companies Morgan Stanley analysts predict will receive tender offers within the next 12 months. Analysts used proprietary quantitative models to issue its predictions. The models relied on a combination of cohort information and stock-level fundamental data to forecast acquisition likelihood, among other data.
Here are 10 companies likely to be acquired by the end of next year along with their market cap estimate, according to Business Insider:
1. Iqiva — $26.4 billion
2. Biomarin Pharmaceutical — $17.6 billion
3. Seattle Genetics — $12.9 billion
4. DaVita — $12.4 billion
5. Universal Health Services (King of Prussia, Pa.) — $11.7 billion
6. Dexcom — $11.5 billion
7. Neurocrine Biosciences — $10.8 billion
8. Perrigo — $9.8 billion
9. Nektar Therapeutics — $9.5 billion
10. Sarepta Therapeutics — $9.5 billion
To access the full report, click here.
More articles on transactions and valuations:
PwC: Healthcare M&A surpasses 250 deals for 5th consecutive quarter
Texas hospital that abruptly closed in May, laid off 900 finds new operator
HCA-Mission Health deal requires intense scrutiny, ex-Missouri governor says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
